Xiaoyuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyuan Wang has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wu
Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
19 shared publications - Dongxin Lin
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
19 shared publications - Guoyu Cheng
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
18 shared publications - Jiang Chang
Department of Health Toxicology, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College Huazhong University of Science and Technology Wuhan China
18 shared publications - Lan Lan
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
18 shared publications - Li Zhang
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
18 shared publications
Latest Publications
- Open Access
Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC
Background: Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma (ESCC); however, the underlying mechanisms and associated biomarkers that determine treatment response remain unclear. Objective: We delineate the mechanisms underlying the response and resistance, and elucidate the immune features that enhance neoadjuvant PD-L1 blockade efficacy in ESCC. Design: Here, we characterise the cellular dynamics following neoadjuvant PD-L1 blockade via analysing the single-cell transcriptomes of 210 978 cells and spatial transcriptomes of 20 tissue sections. Results: We identify coordinated cellular programmes centred on CXCL13 + CD8 + exhausted T cells, TNFRSF9 + CD4 + regulatory T cells, atypical memory B cells and APOE + macrophages, which coordinate the responses to neoadjuvant PD-L1 blockade at baseline. In post-treatment non-responder ESCCs, the cellular programmes exhibit an immunosuppressive phenotype, leading to the failure of therapeutic benefits. Furthermore, we reveal that lymphocyte activation gene 3 serves as a potential target and can potentiate the response via perturbation of the coordinated cellular programmes. Conclusions: Overall, our findings unravel the coordinated cellular programmes associated with treatment response, providing insights for prioritising individualised immunotherapy strategies in ESCC. Trial registration number: ChiCTR2400083452.
Open AccessCoordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC
Background: Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma (ESCC); however, the underlying mechanisms and associated biomarkers that determine treatment response remain unclear. Objective: We delineate the mechanisms underlying the response and resistance, and elucidate the immune features that enhance neoadjuvant PD-L1 blockade efficacy in ESCC. Design: Here, we characterise the cellular dynamics following neoadjuvant PD-L1 blockade via analysing the single-cell transcriptomes of 210 978 cells and spatial transcriptomes of 20 tissue sections. Results: We identify coordinated cellular programmes centred on CXCL13 + CD8 + exhausted T cells, TNFRSF9 + CD4 + regulatory T cells, atypical memory B cells and APOE + macrophages, which coordinate the responses to neoadjuvant PD-L1 blockade at baseline. In post-treatment non-responder ESCCs, the cellular programmes exhibit an immunosuppressive phenotype, leading to the failure of therapeutic benefits. Furthermore, we reveal that lymphocyte activation gene 3 serves as a potential target and can potentiate the response via perturbation of the coordinated cellular programmes. Conclusions: Overall, our findings unravel the coordinated cellular programmes associated with treatment response, providing insights for prioritising individualised immunotherapy strategies in ESCC. Trial registration number: ChiCTR2400083452.
- Open Access
- 25 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10165
Mutant TP53 hijacks RNA-splicing factor RBM28 to suppress double-stranded RNA triggered antitumor immunity
TP53 mutation may not only compromise its multifaceted tumor-suppressive functions but also confer oncogenic properties. Here, we demonstrate that DNA-binding domain mutations of TP53 unexpectedly confer a transcriptional regulatory function, directly driving RNA-splicing factor RBM28 overexpression. Overexpressed RBM28 excessively splices transposon elements, inhibiting double-stranded RNA (dsRNA) formation, thereby suppressing dsRNA-triggered type I interferon (IFN) signaling and subsequent anti-tumor immunity. We demonstrate in mouse tumorigenesis models and human multi-stage esophageal cancer development that mutant p53 (mutp53)-driven aberrant RBM28/dsRNA/IFN axis plays a crucial role in cancer initiation, progression and resistance to immune checkpoint blockade (ICB) therapy through innate immune suppression. Pan-cancer analysis indicates that this mechanism underlies ICB resistance in most cancers. Pharmacological restoration of normal p53 conformation or targeted RNA-splicing inhibition enhances anti-tumor immunity and ICB efficacy. Collectively, our study has unveiled an important function of mutp53 in establishing immunosuppressive tumor microenvironment, which provides an actionable framework for intervention and therapy in TP53-mutated cancers.
- 25 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10165
Open AccessMutant TP53 hijacks RNA-splicing factor RBM28 to suppress double-stranded RNA triggered antitumor immunity
TP53 mutation may not only compromise its multifaceted tumor-suppressive functions but also confer oncogenic properties. Here, we demonstrate that DNA-binding domain mutations of TP53 unexpectedly confer a transcriptional regulatory function, directly driving RNA-splicing factor RBM28 overexpression. Overexpressed RBM28 excessively splices transposon elements, inhibiting double-stranded RNA (dsRNA) formation, thereby suppressing dsRNA-triggered type I interferon (IFN) signaling and subsequent anti-tumor immunity. We demonstrate in mouse tumorigenesis models and human multi-stage esophageal cancer development that mutant p53 (mutp53)-driven aberrant RBM28/dsRNA/IFN axis plays a crucial role in cancer initiation, progression and resistance to immune checkpoint blockade (ICB) therapy through innate immune suppression. Pan-cancer analysis indicates that this mechanism underlies ICB resistance in most cancers. Pharmacological restoration of normal p53 conformation or targeted RNA-splicing inhibition enhances anti-tumor immunity and ICB efficacy. Collectively, our study has unveiled an important function of mutp53 in establishing immunosuppressive tumor microenvironment, which provides an actionable framework for intervention and therapy in TP53-mutated cancers.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo